Identifiers | |
---|---|
| |
CAS Number | |
PubChem CID | |
UNII | |
Chemical and physical data | |
Formula | C15H19N |
Molar mass | 213.324 g·mol−1 |
3D model ( JSmol) | |
| |
| |
(verify) |
NEFA is a moderate affinity NMDA antagonist (IC50 = 0.51 μM). It is a structural analog of phencyclidine. [1] It was first synthesized by a team at Parke-Davis in the late 1950s. [2]
AMPARTooltip α-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor |
|
---|---|
KARTooltip Kainate receptor |
|
NMDARTooltip N-Methyl-D-aspartate receptor |
|
This hallucinogen-related article is a stub. You can help Wikipedia by expanding it. |
Identifiers | |
---|---|
| |
CAS Number | |
PubChem CID | |
UNII | |
Chemical and physical data | |
Formula | C15H19N |
Molar mass | 213.324 g·mol−1 |
3D model ( JSmol) | |
| |
| |
(verify) |
NEFA is a moderate affinity NMDA antagonist (IC50 = 0.51 μM). It is a structural analog of phencyclidine. [1] It was first synthesized by a team at Parke-Davis in the late 1950s. [2]
Psychedelics ( 5-HT2A agonists) |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Dissociatives ( NMDAR antagonists) |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Deliriants ( mAChR antagonists) |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Others |
|
AMPARTooltip α-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor |
|
---|---|
KARTooltip Kainate receptor |
|
NMDARTooltip N-Methyl-D-aspartate receptor |
|
This hallucinogen-related article is a stub. You can help Wikipedia by expanding it. |